Primary Hepatoid Adenocarcinoma of the Lung: A Study of Two Cases with Review of Literature

Abstract
Primary hepatoid adenocarcinoma (HAC) is a rare extrahepatic adenocarcinoma with morphological and phenotypical resemblance to hepatocellular carcinoma (HCC). It can occur in lung, stomach, gallbladder, pancreas, ovary, and uterus, with most common site being stomach. Morphological features of primary HAC of the lung are similar to HCC, so exclusion of metastatic HCC is necessary. In this report, we describe two cases of elderly men with primary pulmonary HAC who presented in advanced clinical stage and diagnosed by fine-needle aspiration cytology with immunohistochemistry. Both patients succumbed to death despite starting first cycle of chemotherapy.

Keywords: Cell block, fine-needle aspiration cytology, hepatoid adenocarcinoma, immunohistochemistry, lung

Introduction
Primary hepatoid adenocarcinoma (HAC) is a rare extrahepatic adenocarcinoma that is defined by morphological and functional hepatic differentiation.[1] The most common site of origin is stomach (63%). It rarely involves ovary (10%), lung (5%), gallbladder (4%), pancreas (4%), and uterus (4%).[2] There are only 34 cases of primary HAC of the lung origin that are described in the world literature, of which only one case has been reported from India.[3] In our study, we report two cases of primary HAC of the lung in two male patients which was diagnosed on fine-needle aspiration cytology (FNAC) with ancillary studies. The present study, to best of our knowledge, is the second to report with the comprehensive clinicopathological data of two cases of primary HAC of the lung in the Indian literature.

Case Reports
Case 1
A 66-year-old male chronic smoker presented with chief complaints of pain in the left side of the chest for 2 months with a history of loss of weight and appetite. General physical examination was normal with no peripheral lymphadenopathy. Respiratory system examination showed decreased air entry in the left lung. On percussion, tenderness was noted over the left chest wall. Hematological investigations showed neutrophilic leucocytosis. Biochemical investigations were within normal limits. Serological tests for HIV and hepatitis B were negative. Chest X-ray posteroanterior view revealed an irregular, spiculated large lesion in the lower lobe of the left lung, suggestive of malignancy and ill-defined radiopaque lesion in the mid zone suggestive of consolidation. Contrast-enhanced computed tomography (CECT) of the chest and thorax showed a large heterogeneously enhancing mass lesion measuring 7.6 cm × 7.5 cm × 7.5 cm with nonenhancing areas of necrosis in the superior segment of the lower lobe of the left lung with narrowing of bronchial lumina. The lesion was abutting left inferior pulmonary vein anteriorly, descending aorta medially, and posterior chest wall posteriorly [Figure 1a and b]. Mediastinal lymphadenopathy and pleural effusion were not seen. On bronchoscopy, mucosal edema and narrowing of lumina were noted in the left bronchus. Bronchoalveolar lavage (BAL) fluid for cytology revealed numerous endobronchial cells with no evidence of malignancy, and the culture was positive for Pseudomonas aeruginosa. CT-guided core biopsy was done from the superior segment of lower lobe of the left lung and showed hepatoid adenocarcinoma on histology. The patient was started on first cycle of chemotherapy.
Acid-fast bacilli were not detected in the early morning sputum and BAL analysis. Computed tomography (CT)-guided biopsy was done from the mass lesion. Biopsy tissue was scanty showing large neoplastic cells arranged in the trabeculae pattern with abundant eosinophilic cytoplasm and vesicular nucleus. Immunohistochemistry (IHC) showed neoplastic cells expressing cytoplasmic immunoreactivity to thyroid transcription factor-1 (TTF-1) and negative for CK7 and P40. As tissue was inadequate for further IHC markers, the patient was referred for FNAC and cell block study. Ultrasonography (USG)-guided fine-needle aspiration (FNA) from lung lesion was done. Cytomorphology showed tumor cells in the clusters and discohesive cells. Tumor cells had moderate cytoplasm and vesicular nuclei with prominent nucleoli with intranuclear inclusions in few cells [Figure 2a and b]. Cell block showed neoplastic cells arranged in cords and trabeculae [Figure 2c and d]. IHC was performed on cell block and showed neoplastic cells to be positive for CK, Hep Par-1, and TTF-1 (cytoplasmic) and negative for CK7, CK20, napsin, and p40 [Figure 2e-g]. In view of Hep Par-1 positivity, serum alpha fetoprotein (AFP) and CECT abdomen were suggested to look for primary malignancy in the liver. Serum AFP level was elevated to 394.60 IU/ml. CECT abdomen and pelvis showed normal liver with no focal lesion. Other intra-abdominal and pelvic organs were normal. Second panel of IHC markers on cell block was advised which revealed tumor cells to be positive for AFP [Figure 2h] and negative for arginase and CK5/6. Correlating with clinical and radiological findings, final impression of hepatoid variant of adenocarcinoma of the left lung was given.

Further metastatic workup showed normal skeletal scintigraphy; glomerular filtration rate values were within normal limits. Positron emission tomography (PET)-CT showed metabolically active lesion in the lower lobe of the left lung with a few lung nodules and lymph nodes (hilar and mediastinal), representing carcinoma lung with metastasis. The patient was assigned clinical stage cT3N2M0 (Stage IIIA). No other visceral or skeletal metastasis was seen [Figure 1c and d]. Chemotherapy was started; however, unfortunately, the patient succumbed to the disease after first cycle of chemotherapy.

Case 2

A 65-year-old man presented with chief complaints of pain in the right side of the chest and breathlessness for 2 months. He was a chronic smoker for 20 years and had a history of recent significant weight loss and loss of appetite. General physical examination was normal, except for pallor. Respiratory system examination revealed decreased air entry in the right lung and audible crypts. Right chest wall tenderness was noted on percussion. Laboratory investigations, hemogram, and biochemical tests were within normal limits. Serology for hepatitis B virus and HIV were nonreactive. Chest X-ray posteroanterior view revealed a large lesion in the right upper zone, suggestive of malignancy. CECT thorax showed a heterogeneously enhancing lesion measuring 6.5 cm × 4.5 cm × 6.6 cm in the posterior segment of the upper lobe of the right lung with extension into apical segment. The lesion was extending along major fissure up to lateral costal pleura and right hilar region. Anteriorly, it was abutting the trachea, right main bronchus, right upper lobe bronchus, azygos vein, and superior vena cava. Posteriorly, the lesion was abutting the T3, T4, T5, and T6 vertebral bodies.
and the corresponding posterior aspect of 3rd, 4th, 5th, and 6th ribs. Mediastinal lymph nodes were enlarged largest measuring 7.3 mm. A very tiny hypodense lesion of size 0.3 cm was noted in the liver segment Iva, suggestive of nonspecific inflammation. Bilateral kidneys showed multiple subcentimetric simple cysts.

USG-guided FNA of the lung mass was done. Cytomorphology was similar to previous case [Figure 3a-c]. IHC was performed on cell block and neoplastic cells were positive for CK, CK7, and TTF-1 (granular cytoplasmic) and negative for CK20, p40, and napsin [Figure 3d-f]. Further, IHC markers were advised, for which clinicians decided to do biopsy since cell block tissue was scanty. IHC on tissue biopsy showed neoplastic cells immunoreactive for CK7, AFP, and Hep Par-1 with cytoplasmic positivity for TTF-1. Serum AFP level was raised (993.6 IU/ml). In view of raised serum AFP and its classical immunoreactivity in tumor cells in the absence of significant liver lesion, a diagnosis of primary HAC right lung was made. Further metastatic workup showed normal skeletal scintigraphy. A clinical stage cT2bN2M0 (Stage IIIA) was assigned to the patient. Chemotherapy was started, but the patient expired.

**Discussion**

Primary HAC is a rare extrapulmonary adenocarcinoma that is defined by morphological and functional hepatic differentiation. This entity was descriptively termed as “hepatoid” due to the morphological appearance, and it should be differentiated from other adenocarcinomas. The most common site of origin is stomach (63%). It rarely involves ovary (10%), lung (5%), gallbladder (4%), pancreas (4%), and uterus (4%). HAC of the lung origin was first described by Ishikura et al. in 1990. They proposed two criteria which were adopted uniformly for diagnosis of HAC:

1. Adenocarcinomatous component composed of neoplastic cells in the tubular or papillary architecture
2. Hepatoid component resembling hepatocellular carcinoma (HCC); the neoplastic cells containing abundant eosinophilic cytoplasm with centrally placed nucleus. These cells are responsible for AFP production.

Our both cases fulfilled all criteria.

A comprehensive search was conducted on PubMed, Google, and Google Scholar using terms of “hepatoid adenocarcinoma lung,” hepatoid carcinoma lung,” and “AFP producing tumor lung.” We found that only 34 cases of primary HAC lung have been reported in the world literature before December 2018. Grossman et al. reviewed 28 cases of HAC lung reported in the English literature, between January 1980 and June 2015. Additional six case reports have been published from June 2015 to December 2018 including one Indian case report by Vellaisamy et al.

In these reported 34 cases of primary HAC lung, 33 were males with age ranging from 36 to 77 years (mean 57 years). History of chronic smoking was significant in 19 cases, suggesting that this neoplasm is common in middle to old age men and chronic smoking can be a predisposing factor. In the present report, the clinical features, smoking habit, signs, and symptoms of airway obstruction are similar to the world literature. Primary HAC is a very aggressive tumor with most of the patients presenting with higher stage of disease, distant metastasis, and shorter survival. The maximum survival of 9 years was reported by Haninger et al. in a female with stage T1A HAC.

Regarding the cell of origin of primary HAC, following hypotheses were adopted:

1. Embryologically, lung, liver, and stomach derived from the primitive foregut. It is hypothesized that
hepatoid differentiation may occur at many diverse sites (stomach being most common) as another direction of differentiation of primitive neoplastic cells in adenocarcinoma.[14]

2. The theory of “ectopic hepatoma” postulated that HAC in the lung arises from ectopic germ cells or liver cells in the lung or respiratory epithelium progenitors.[8] These hepatoid cells are AFP immunoreactive and responsible for AFP production which is used as one of the diagnostic criteria and useful indicator to monitor tumor progression and response to treatment.[4] In the present study, both cases showed elevated AFP levels.

Morphological features of primary HAC of the lung are similar to HCC, so exclusion of metastatic HCC is necessary before calling it as of lung origin.[1] Multislice CT abdomen or PET-CT abdomen are reliable investigations to rule out metastatic HCC by documenting the absence of liver lesion.[9] Although there are no specific imaging features to diagnose HAC directly, certain features are of concern such as detection of inhomogeneous areas and large necrotic areas on CT.[10] Hence, imaging for detection has a limited role but serves useful in the selection of a therapeutic schedule for HAC, as it is able to detect lymph node or distant metastases and help to assess the clinical stage.[9] In the present study, both cases showed heterogeneous areas with the first one having necrotic areas and the second one being extending to costal pleura. The first case has no lesion in liver; however, other case showed a tiny 3 mm lesion in the liver having nonspecific inflammatory etiology.

Distinguishing between HAC and HCC is important, especially in areas with a high incidence of chronic hepatitis B, chronic hepatitis C, and HCC. When there are concomitant lesions in the lung and liver, it is difficult to differentiate primary HAC from HCC metastasis on morphologic grounds alone. Differences in immunohistochemical expression of certain markers would be of considerable help though HAC shows immunophenotype similar to HCC. CK8, CK18, AFP, Hep Par-1, and TTF1 (cytoplasmic) are positive whereas CK5/6 and CK20 are negative in both HAC and HCC.[1,15] CK7 can be negative[16] or positive in HAC.[1,15] Some antibodies used to differentiate HAC from HCC are EpCAM markers such as HEA125, MOC31 and monoclonal CEA and CK19 which are positive in HAC but negative in HCC.[1,2,17] In the present report, primary HCC was ruled out primarily by radiological investigations since IHC markers which help to distinguish HCC from HAC are not available with us. Pattern of TTF-1 staining which is cytoplasmic is useful to distinguish HAC from conventional adenocarcinoma of the lung.[1]

Primary modality of treatment depends on stage of tumor. Early-stage HAC lung was treated primarily by resection of tumor followed by chemotherapy and radiotherapy. Advanced-stage neoplasm with poor resectability is given chemotherapy and radiotherapy only.[5]

Primary HAC is an uncommon malignancy and lung is the rare site of occurrence. Clinically, the patient presents at late stage of disease with poor survival. Morphologically, primary HAC lung resembles HCC from liver, and therefore, it is important to differentiate between these two entities by IHC and/or radiological investigations as prognosis and treatment may differ. Metastatic carcinoma from HAC should be included in the differential diagnosis in older patients with elevated serum AFP level and hepatic masses with imaging features of HCC in the absence of risk factors of HCC.[18]

### Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have...
given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References